Illumina to face EU fine of 10% of turnover due to Grail deal, Reuter says

Illumina, a U.S. based life sciences firm, will most probably be fined ‘the maximum penalty’ by the EU for closing its acquisition "of Grail without waiting for EU antitrust approval," people with knowledge of the matter said, reports Foo Yun Chee for Reuters. According to people familiar with the matter, Illumina argued its case before senior EC and national competition regulators in December, but the officials remained unconvinced, added Reuters."We disagree that the Commission has jurisdiction to review the GRAIL transaction as well as with the premise of the Commission imposing a fine," said Illumina in an emailed statement, according to the Reuters story. Reference Link